Adagene (ADAG) Competitors $1.59 +0.07 (+4.61%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADAG vs. ATYR, ATAI, PVLA, AURA, CYRX, GLUE, PHAT, RNAC, TSVT, and MNPRShould you be buying Adagene stock or one of its competitors? The main competitors of Adagene include Atyr PHARMA (ATYR), Atai Life Sciences (ATAI), Palvella Therapeutics (PVLA), Aura Biosciences (AURA), Cryoport (CYRX), Monte Rosa Therapeutics (GLUE), Phathom Pharmaceuticals (PHAT), Cartesian Therapeutics (RNAC), 2seventy bio (TSVT), and Monopar Therapeutics (MNPR). These companies are all part of the "pharmaceutical products" industry. Adagene vs. Atyr PHARMA Atai Life Sciences Palvella Therapeutics Aura Biosciences Cryoport Monte Rosa Therapeutics Phathom Pharmaceuticals Cartesian Therapeutics 2seventy bio Monopar Therapeutics Atyr PHARMA (NASDAQ:ATYR) and Adagene (NASDAQ:ADAG) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, community ranking, analyst recommendations, risk and earnings. Do institutionals & insiders believe in ATYR or ADAG? 61.7% of Atyr PHARMA shares are held by institutional investors. Comparatively, 9.5% of Adagene shares are held by institutional investors. 3.7% of Atyr PHARMA shares are held by company insiders. Comparatively, 21.2% of Adagene shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media refer more to ATYR or ADAG? In the previous week, Atyr PHARMA had 3 more articles in the media than Adagene. MarketBeat recorded 7 mentions for Atyr PHARMA and 4 mentions for Adagene. Adagene's average media sentiment score of 0.96 beat Atyr PHARMA's score of 0.79 indicating that Adagene is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atyr PHARMA 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adagene 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings and valuation, ATYR or ADAG? Adagene has lower revenue, but higher earnings than Atyr PHARMA. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtyr PHARMA$235K1,262.93-$50.39M-$0.87-3.84Adagene$103.20K723.51-$18.95MN/AN/A Do analysts rate ATYR or ADAG? Atyr PHARMA currently has a consensus price target of $18.60, suggesting a potential upside of 456.89%. Adagene has a consensus price target of $8.00, suggesting a potential upside of 404.73%. Given Atyr PHARMA's stronger consensus rating and higher possible upside, equities research analysts clearly believe Atyr PHARMA is more favorable than Adagene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atyr PHARMA 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Adagene 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is ATYR or ADAG more profitable? Adagene's return on equity of 0.00% beat Atyr PHARMA's return on equity.Company Net Margins Return on Equity Return on Assets Atyr PHARMAN/A -79.44% -59.16% Adagene N/A N/A N/A Which has more volatility & risk, ATYR or ADAG? Atyr PHARMA has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500. Comparatively, Adagene has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500. Does the MarketBeat Community favor ATYR or ADAG? Adagene received 10 more outperform votes than Atyr PHARMA when rated by MarketBeat users. However, 100.00% of users gave Atyr PHARMA an outperform vote while only 79.31% of users gave Adagene an outperform vote. CompanyUnderperformOutperformAtyr PHARMAOutperform Votes13100.00% Underperform VotesNo VotesAdageneOutperform Votes2379.31% Underperform Votes620.69% SummaryAtyr PHARMA beats Adagene on 10 of the 16 factors compared between the two stocks. Get Adagene News Delivered to You Automatically Sign up to receive the latest news and ratings for ADAG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADAG vs. The Competition Export to ExcelMetricAdagenePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$74.67M$6.69B$5.47B$7.92BDividend YieldN/A3.05%5.11%4.22%P/E RatioN/A7.3222.5118.54Price / Sales723.51241.49397.62103.35Price / CashN/A65.8538.1834.62Price / Book0.986.486.734.25Net Income-$18.95M$143.41M$3.22B$248.18M7 Day Performance15.69%2.30%1.58%1.25%1 Month Performance-12.67%7.14%4.05%3.76%1 Year Performance-31.97%-2.61%15.75%5.28% Adagene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADAGAdagene2.6319 of 5 stars$1.59+4.3%$8.00+404.7%-32.7%$74.67M$103,204.000.00260Short Interest ↓News CoverageATYRAtyr PHARMA2.5624 of 5 stars$3.28+5.8%$18.60+467.1%N/A$291.46M$235,000.00-3.4953Short Interest ↑News CoverageATAIAtai Life Sciences2.6868 of 5 stars$1.42-3.4%$10.50+639.4%-24.2%$283.69M$308,000.00-1.7580PVLAPalvella Therapeutics3.4144 of 5 stars$25.45+4.5%$44.43+74.6%N/A$280.43M$42.81M-2.10N/AAnalyst ForecastPositive NewsHigh Trading VolumeAURAAura Biosciences2.334 of 5 stars$5.57+3.9%$22.75+308.4%-21.2%$279.75MN/A-3.2250Upcoming EarningsShort Interest ↑News CoverageGap DownCYRXCryoport2.3869 of 5 stars$5.52-0.5%$11.67+111.4%-65.5%$275.50M$228.39M-1.631,020Upcoming EarningsGLUEMonte Rosa Therapeutics1.9755 of 5 stars$4.46-2.0%$15.50+247.5%-7.7%$274.34M$75.62M-2.4490Upcoming EarningsShort Interest ↑News CoveragePositive NewsPHATPhathom Pharmaceuticals4.0455 of 5 stars$3.90-3.2%$21.83+459.8%-52.5%$271.58M$55.25M-0.69110News CoveragePositive NewsGap DownRNACCartesian Therapeutics1.9639 of 5 stars$10.34-1.5%$42.14+307.6%-45.6%$267.88M$38.91M-0.2064Upcoming EarningsPositive NewsTSVT2seventy bio1.7593 of 5 stars$4.99+0.2%$5.60+12.2%+9.4%$261.17M$37.86M-2.68440Short Interest ↑News CoverageMNPRMonopar Therapeutics2.8845 of 5 stars$42.71+7.9%$55.33+29.6%+1,167.1%$261.09MN/A-21.6810Upcoming EarningsNews Coverage Related Companies and Tools Related Companies ATYR Competitors ATAI Competitors PVLA Competitors AURA Competitors CYRX Competitors GLUE Competitors PHAT Competitors RNAC Competitors TSVT Competitors MNPR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADAG) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredMassive dollar overhaul underway in D.C.?Trump's plan to save the U.S. Dollar The U.S. Dollar is crashing, and our reserve currency status is now in...Stansberry Research | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adagene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adagene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ADAG Stock Free ADAG Stock Alerts